NOVARTIS AG |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 95.76 CHF | -3.33% |
|
-2.28% | +14.32% |
| 01:54pm | Trending : Novartis Raises Profit Guidance as It Prepares for Patent Expirations | DJ |
| 01:33pm | Stocks Mostly Up Pre-Bell as Investors Await More Earnings; Asia Churns, Europe Down | MT |
| Sales 2024 * | 49.29B 43.59B 4,120B | Sales 2025 * | 51.41B 45.46B 4,297B | Capitalization | 228B 202B 19,089B |
|---|---|---|---|---|---|
| Net income 2024 * | 10.76B 9.51B 899B | Net income 2025 * | 12.22B 10.81B 1,022B | EV / Sales 2024 * | 4.9 x |
| Net Debt 2024 * | 13.22B 11.69B 1,105B | Net Debt 2025 * | 11.6B 10.26B 969B | EV / Sales 2025 * | 4.67 x |
| P/E ratio 2024 * |
21.7
x | P/E ratio 2025 * |
18.8
x | Employees | 76,057 |
| Yield 2024 * |
3.31% | Yield 2025 * |
3.43% | Free-Float | 85.22% |
More Fundamentals
* Assessed data
More news
Latest transcript on Novartis AG
More press releases
More news
| 1 day | -3.37% | ||
| 1 week | -3.17% | ||
| Current month | -0.04% | ||
| 1 month | +3.20% | ||
| 3 months | +13.74% | ||
| 6 months | +3.23% | ||
| Current year | +13.27% |
1 week
95.86
100.96
1 month
92.80100.96
Current year
83.63100.96
1 year
83.00100.96
3 years
72.84100.96
5 years
65.09100.96
10 years
65.09103.20
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 48 | 01/05/01 | |
| Director of Finance/CFO | 59 | 01/03/01 | |
Shreeram Aradhye
CTO | Chief Tech/Sci/R&D Officer | 62 | 16/22/16 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Bill Winters
BRD | Director/Board Member | 62 | 01/13/01 |
Simon Moroney
BRD | Director/Board Member | 65 | 28/20/28 |
| Chairman | 68 | 01/13/01 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 10.40% | 121 M€ | -.--% | - | |
| 5.57% | 14 M€ | +11.35% | - | |
| 4.12% | 88 M€ | +10.37% | - | |
| 3.79% | 2 M€ | -25.75% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 18/24/18 | 95.81 | -3.28% | 1 647 563 |
| 17/24/17 | 99.06 | +0.16% | 3,512,848 |
| 16/24/16 | 98.9 | -0.20% | 2,133,566 |
| 15/24/15 | 99.1 | -0.96% | 2,183,223 |
| 12/24/12 | 100.1 | +0.79% | 2,652,925 |
Delayed Quote Swiss Exchange, July 18, 2024 at 05:33 pm IST
More quotes
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows:
- oncology (29.9%);
- immunology (17.2%);
- cardiovascular, renal and metabolic diseases (14.1%);
- neuroscience (8.9%).
The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products.
At the end of 2023, Novartis AG had 33 production sites worldwide.
Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).
Sector
Pharmaceuticals
Calendar
10:30am
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
111.9
USD
Average target price
113
USD
Spread / Average Target
+0.96%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +13.27% | 228B | |
| +55.35% | 815B | |
| +32.03% | 597B | |
| -0.10% | 377B | |
| +15.47% | 319B | |
| +13.10% | 310B | |
| +12.84% | 250B | |
| +16.38% | 247B | |
| +16.54% | 180B | |
| +4.31% | 170B |
- Stock Market
- Equities
- NOVN Stock
